Melanoma Clinical Trials

Showing 821-840 of 1,292 trials

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

NCT01866319

This study will evaluate the safety and efficacy of 2 different dosing schedules of pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2 schedules to treatment with ipilimumab in ipilimumab-naïve participants with unresectable or metastatic melanoma. The primary hypotheses are that pembrolizumab is superior to ipilimumab with respect to progression-free survival (PFS) and overall survival (OS).

Melanoma

Merck Sharp & Dohme LLC834 participantsStarted Aug 2013

TERMINATEDPhase 1

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

NCT01826448

The purpose of this research study is to test the safety of an investigational new drug called PLX3397 when used in combination with Vemurafenib (Zelboraf™) at different dose levels. Vemurafenib has been approved by the United States Food and Drug Administration (FDA)/European Medicines Agency (EMA) for the treatment of a specific category of unresectable or metastatic melanoma.

V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

Daiichi Sankyo13 participantsStarted Nov 2013

Los Angeles, California, United States • Aurora, Colorado, United States • Nashville, Tennessee, United States +3 more locations

TERMINATEDPhase 1

Safety of ADU-1604 in Adults With Metastatic Melanoma

NCT03674502

This study is a first-in-human, open-label, multicenter, dose-escalation study designed to evaluate the safety, PK, and PD of ADU-1604 and explore initial clinical activity in adults with metastatic melanoma.

Metastatic Melanoma

Aduro Biotech, Inc.4 participantsStarted Nov 2018

Marseille, France • Paris, France • Villejuif, France +2 more locations

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Safety of ADU-1604 in Adults With Metastatic Melanoma

Related Searches

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Spanish Registry of Mohs Surgery

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

Correlation of Early Postoperative Scar Appearance With Long-term Scar Outcomes

The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma

Health Communication in Families

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Suicide Plus Immune Gene Therapy for Advanced Melanoma

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

PVSRIPO in Combination With Nivolumab in Melanoma